Viatris formation from Mylan-Upjohn merger (2020)
Pfizer spun off its off-patent branded drug unit Upjohn and merged it with generic drug maker Mylan to create Viatris, a new company that needed to prove it could grow as an independent entity. Viatris started with roughly $17 billion in annual revenue but faced investor skepticism about whether combining two mature, slow-growth businesses would create value.
Viatris stock declined significantly in its first two years as an independent company, dropping from around $18 at launch to under $10, as investors questioned the growth thesis.
Viatris eventually pursued acquisitions and portfolio reshaping to find growth, mirroring the challenge facing any newly independent company carved out of a larger parent.
Embecta faces a nearly identical challenge: a mature business separated from a large parent, with a declining stock price and a strategy that depends on acquisitions to transform from a single-product company into a diversified platform. The Owen Mumford deal is Embecta's first test of whether M&A can reverse the post-spinoff trajectory.